Protective LRRK2 R1398H variant enhances GTPase and Wnt signaling activity

Frontiers in Molecular Neuroscience

Volumn 9, Issue MAR, 2016, Pages

  Nixon Abell, Jonathon ^a,b   Berwick, Daniel C ^a,c   Grannó, Simone ^a   Spain, Victoria A ^a   Blackstone, Craig ^b   Harvey, Kirsten ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c OPEN UNIVERSITY   (United Kingdom)

Author keywords

GTPase activity; LRRK2; Parkinson s disease; Protective genetic variant; Wnt signaling

Indexed keywords

GUANOSINE TRIPHOSPHATASE; GUANOSINE TRIPHOSPHATE; LEUCINE RICH REPEAT KINASE 2; LUCIFERASE; PLASMID VECTOR;

ARTICLE; BINDING ASSAY; BRAIN CELL CULTURE; CONTROLLED STUDY; DIMERIZATION; ENZYME ASSAY; GENE MUTATION; GENETIC TRANSFECTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HYDROLYSIS; LUCIFERASE ASSAY; MOLECULAR CLONING; MOLECULAR MODEL; NERVE FIBER GROWTH; NERVE FIBER LENGTH; NERVE FUNCTION; NERVOUS SYSTEM PARAMETERS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN BINDING; PROTEIN INTERACTION; REGULATORY MECHANISM; TWO HYBRID SYSTEM; WNT SIGNALING PATHWAY;

EID: 84961711549     PISSN: 16625099     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnmol.2016.00018     Document Type: Article

References (60)

1. Aasly, J. O. Vilariño-Güell, C. Dachsel, J. C. Webber, P. J. West, A. B. Haugarvoll, K. et al. (2010). Novel pathogenic LRRK2 p. Asn1437His substitution in familial Parkinson's disease. Mov. Disord. 25, 2156-2163. doi: 10. 1002/mds. 23265
2. Arenas, E. (2014). Wnt signaling in midbrain dopaminergic neuron development and regenerative medicine for Parkinson's disease. J. Mol. Cell Biol. 6, 42-53. doi: 10. 1093/jmcb/mju001
3. Berwick, D. C. and Harvey, K. (2011). LRRK2 signaling pathways. The key to unlocking neurodegeneration? Trends Cell Biol. 21, 257-265. doi: 10. 1016/j. tcb. 2011. 01. 001
4. Berwick, D. C. and Harvey, K. (2012). LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6. Hum. Mol. Genet. 21, 4966-4979. doi: 10. 1093/hmg/dds342
5. Berwick, D. C. and Harvey, K. (2013). LRRK2: an éminence grise of Wnt-mediated neurogenesis? Front. Cell. Neurosci. 7:82. doi: 10. 3389/fncel. 2013. 00082
6. Berwick, D. C. and Harvey, K. (2014). The regulation and deregulation of Wnt signaling by PARK genes in health and disease. J. Mol. Cell. Biol. 6, 3-12. doi: 10. 1093/jmcb/mjt037
7. Biosa, A. Trancikova, A. Civiero, L. Glauser, L. Bubacco, L. Greggio, E. et al. (2013). GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2. Hum. Mol. Genet. 22, 1140-1156. doi: 10. 1093/hmg/dds522
8. Boon, J. Y. Dusonchet, J. Trengrove, C. and Wolozin, B. (2014). Interaction of LRRK2 with kinase and GTPase signaling cascades. Front. Mol. Neurosci. 7:64. doi: 10. 3389/fnmol. 2014. 00064
9. Bosgraaf, L. and van Haastert, P. J. (2003). Roc, a Ras/GTPase domain in complex proteins. Biochim. Biophys. Acta 1643, 5-10. doi: 10. 1016/j. bbamcr. 2003. 08. 008
10. Cantuti-Castelvetri, I. Keller-McGandy, C. Bouzou, B. Asteris, G. Clark, T. W. Frosch, M. P. et al. (2007). Effects of gender on nigral gene expression and parkinson disease. Neurobiol. Dis. 26, 606-614. doi: 10. 1016/j. nbd. 2007. 02. 009
11. Chen, L. Zhang, S. Liu, Y. Hong, H. Wang, H. Zheng, Y. et al. (2010). LRRK2 R1398H polymorphism is associated with decreased risk of Parkinson's disease in a Han Chinese population. Parkinsonism Relat. Disord. 17, 291-292. doi: 10. 1016/j. parkreldis. 2010. 11. 012
12. Cho, H. J. Liu, G. Jin, S. M. Parisiadou, L. Xie, C. Yu, J. et al. (2013). MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein. Hum. Mol. Genet. 22, 608-620. doi: 10. 1093/hmg/dds470
13. Dächsel, J. C. Behrouz, B. Yue, M. Beevers, J. E. Melrose, H. L. and Farrer, M. J. (2010). A comparative study of Lrrk2 function in primary neuronal cultures. Parkinsonism Relat. Disord. 16, 650-655. doi: 10. 1016/j. parkreldis. 2010. 08. 018
14. Daniëls, V. Vancraenenbroeck, R. Law, B. M. Greggio, E. Lobbestael, E. Gao, F. et al. (2011). Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J. Neurochem. 116, 304-315. doi: 10. 1111/j. 1471-4159. 2010. 07105. x
15. Deng, J. Lewis, P. A. Greggio, E. Sluch, E. Beilina, A. and Cookson, M. R. (2008). Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc. Natl. Acad. Sci. U. S. A. 105, 1499-1504. doi: 10. 1073/pnas. 0709098105
16. Dunbrack, R. L. (2002). Rotamer libraries in the 21st century. Curr. Opin. Struct. Biol. 12, 431-440. doi: 10. 1016/S0959-440X(02)00344-5
17. Gasper, R. Meyer, S. Gotthardt, K. Sirajuddin, M. and Wittinghofer, A. (2009). It takes two to tango: regulation of G proteins by dimerization. Nat. Rev. Mol. Cell. Biol. 10, 423-429. doi: 10. 1038/nrm2689
18. Gilsbach, B. K. and Kortholt, A. (2014). Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation. Front. Mol. Neurosci. 7:32. doi: 10. 3389/fnmol. 2014. 00032
19. Gollamudi, S. Johri, A. Calingasan, N. Y. Yang, L. Elemento, O. and Beal, M. F. (2012). Concordant signaling pathways produced by pesticide exposure in mice correspond to pathways identified in human Parkinson's disease. PLoS ONE 7:e36191. doi: 10. 1371/journal. pone. 0036191
20. Gómez-Suaga, P. Fdez, E. Fernández, B. Martínez-Salvador, M. Blanca Ramírez, M. Madero-Pérez, J. et al. (2014). Novel insights into the neurobiology underlying LRRK2-linked Parkinson's disease. Neuropharmacology 85, 45-56. doi: 10. 1016/j. neuropharm. 2014. 05. 020
21. Gotthardt, K. Weyand, M. Kortholt, A. Van Haastert, P. J. and Wittinghofer, A. (2008). Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase. EMBO J. 27, 2239-2249. doi: 10. 1038/emboj. 2008. 150
22. Heckman, M. G. Elbaz, A. Soto-Ortolaza, A. I. Serie, D. J. Aasly, J. O. Annesi, G. et al. (2014). Protective effect of LRRK2 p. R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants. Neurobiol. Aging 35:e5-e14. doi: 10. 1016/j. neurobiolaging. 2013. 07. 013
23. Heckman, M. G. Soto-Ortolaza, A. I. Aasly, J. O. Abahuni, N. Annesi, G. Bacon, J. A. et al. (2013). Population-specific frequencies for LRRK2 susceptibility variants in the genetic epidemiology of Parkinson's disease (GEO-PD) Consortium. Mov. Disord. 12, 1740-1744. doi: 10. 1002/mds. 25600
24. Huang, Y. Halliday, G. M. Vandebona, H. Mellick, G. D. Mastaglia, F. Stevens, J. et al. (2007). Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease. Mov. Disord. 22, 982-989.
25. Inestrosa, N. C. and Arenas, E. (2010). Emerging roles of Wnts in the adult nervous system. Nat. Rev. Neurosci. 11, 77-86. doi: 10. 1038/nrn2755
26. Inestrosa, N. C. and Varela-Nallar, L. (2014). Wnt signaling in the nervous system and in Alzheimer's disease. J. Mol. Cell. Biol. 6, 64-74. doi: 10. 1093/jmcb/mjt051
27. Jaleel, M. Nichols, R. J. Deak, M. Campbell, D. G. Gillardon, F. Knebel, A. et al. (2007). LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem. J. 405, 307-317. doi: 10. 1042/BJ20070209
28. Klein, C. L. Rovelli, G. Springer, W. Schall, C. Gasser, T. and Kahle, P. J. (2009). Homo-and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment. J. Neurochem. 111, 703-715. doi: 10. 1111/j. 1471-4159. 2009. 06358. x
29. Korr, D. Toschi, L. Donner, P. Pohlenz, H. D. Kreft, B. and Weiss, B. (2006). LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domain. Cell Signal. 18, 910-920. doi: 10. 1016/j. cellsig. 2005. 08. 015
30. Kumari, U. and Tan, E. K. (2009). LRRK2 in Parkinson's disease. Genetic and clinical studies from patients. FEBS J. 276, 6455-6463. doi: 10. 1111/j. 1742-4658. 2009. 07344. x
31. Law, B. M. Spain, V. A. Leinster, V. H. Chia, R. Beilina, A. Cho, H. J. et al. (2014). A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylation. J. Biol. Chem. 289, 895-908. doi: 10. 1074/jbc. M113. 507913
32. L'Episcopo, F. Tirolo, C. Caniglia, S. Testa, N. Morale, M. C. Serapide, M. F. et al. (2014). Targeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson's disease. J. Mol. Cell Biol. 6, 13-26. doi: 10. 1093/jmcb/mjt053
33. L'Episcopo, F. Tirolo, C. Testa, N. Caniglia, S. Morale, M. C. Cossetti, C. et al. (2011). Reactive astrocytes and Wnt/β-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Neurobiol. Dis. 41, 508-527. doi: 10. 1016/j. nbd. 2010. 10. 023
34. Lewis, P. A. Greggio, E. Beilina, A. Jain, S. Baker, A. and Cookson, M. R. (2007). The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem. Biophys. Res. Commun. 357, 668-671. doi: 10. 1016/j. bbrc. 2007. 04. 006
35. Li, T. He, X. Thomas, J. M. Yang, D. Zhong, S. Xue, F. et al. (2015). A novel GTP-binding inhibitor, FX2149, attenuates LRRK2 toxicity in Parkinson's disease models. PLoS ONE 10:e0122461. doi: 10. 1371/journal. pone. 0122461
36. Li, T. Yang, D. Zhong, S. Thomas, J. M. Xue, F. Liu, J. et al. (2014). Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models. Hum. Mol. Genet. 23, 6212-6222. doi: 10. 1093/hmg/ddu341
37. Li, X. Tan, Y. C. Poulose, S. Olanow, C. W. Huang, X. Y. and Yue, Z. (2007). Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J. Neurochem. 103, 238-247.
38. Liao, J. Wu, C. X. Burlak, C. Zhang, S. Sahm, H. Wang, M. et al. (2014). Parkinson disease-associated mutation R1441H in LRRK2 prolongs the "active state" of its GTPase domain. Proc. Natl. Acad. Sci. U. S. A. 111, 4055-4060. doi: 10. 1073/pnas. 1323285111
39. Lin, C. H. Tsai, P. I. Wu, R. M. and Chien, C. T. (2010). LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3β. J. Neurosci. 30, 13138-13149. doi: 10. 1523/JNEUROSCI. 1737-10. 2010
40. MacLeod, D. Dowman, J. Hammond, R. Leete, T. Inoue, K. and Abeliovich, A. (2006). The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52, 587-593. doi: 10. 1016/j. neuron. 2006. 10. 008
41. Margalit, D. N. Romberg, L. Mets, R. B. Hebert, A. M. Mitchison, T. J. Kirschner, M. W. et al. (2004). Targeting cell division: small-molecule inhibitors of FtsZ GTPase perturb cytokinetic ring assembly and induce bacterial lethality. Proc. Natl. Acad. Sci. U. S. A. 101, 11821-11826. doi: 10. 1073/pnas. 0404439101
42. Nichols, R. J. Dzamko, N. Morrice, N. A. Campbell, D. G. Deak, M. Ordureau, A. et al. (2010). 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem. J. 430, 393-404. doi: 10. 1042/BJ20100483
43. Paisán-Ruíz, C. Jain, S. Evans, E. W. Gilks, W. P. Simón, J. van der Brug, M. et al. (2004). Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600. doi: 10. 1016/j. neuron. 2004. 10. 023
44. Parisiadou, L. Xie, C. Cho, H. J. Lin, X. Gu, X. L. Long, C. X. et al. (2009). Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J. Neurosci. 29, 13971-13980. doi: 10. 1523/JNEUROSCI. 3799-09. 2009
45. Pettersen, E. F. Goddard, T. D. Huang, C. C. Couch, G. S. Greenblatt, D. M. Meng, E. C. et al. (2004). UCSF Chimera. A visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612. doi: 10. 1002/jcc. 20084
46. Piccoli, G. Condliffe, S. B. Bauer, M. Giesert, F. Boldt, K. De Astis, S. et al. (2011). LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J. Neurosci. 31, 2225-2237. doi: 10. 1523/JNEUROSCI. 3730-10. 2011
47. Pungaliya, P. P. Bai, Y. Lipinski, K. Anand, V. S. Sen, S. Brown, E. L. et al. (2010). Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif. PLoS ONE 5:e13672. doi: 10. 1371/journal. pone. 0013672
48. Ramonet, D. Daher, J. P. Lin, B. M. Stafa, K. Kim, J. Banerjee, R. et al. (2011). Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS ONE 6:e18568. doi: 10. 1371/journal. pone. 0018568
49. Ross, O. A. Soto-Ortolaza, A. I. Heckman, M. G. Aasly, J. O. Abahuni, N. Annesi, G. et al. (2011). Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol. 10, 898-908. doi: 10. 1016/S1474-4422(11)70175-2
50. Ross, O. A. Toft, M. Whittle, A. J. Johnson, J. L. Papapetropoulos, S. Mash, D. C. et al. (2006). Lrrk2 and Lewy body disease. Ann. Neurol. 59, 388-393. doi: 10. 1002/ana. 20731
51. Rudenko, I. N. Kaganovich, A. Hauser, D. N. Beylina, A. Chia, R. Ding, J. et al. (2012). The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation. Biochem. J. 446, 99-111. doi: 10. 1042/BJ20120637
52. Salinas, P. C. (2012). Wnt signaling in the vertebrate central nervous system: from axon guidance to synaptic function. Cold Spring Harb. Perspect. Biol. 4:a008003. doi: 10. 1101/cshperspect. a008003
53. Sancho, R. M. Law, B. M. and Harvey, K. (2009). Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways. Hum. Mol. Genet. 18, 3955-3968. doi: 10. 1093/hmg/ddp337
54. Stafa, K. Trancikova, A. Webber, P. J. Glauser, L. West, A. B. and Moore, D. J. (2012). GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genet. 8:e1002526. doi: 10. 1371/journal. pgen. 1002526
55. Tan, E. K. Peng, R. Teo, Y. Y. Tan, L. C. Angeles, D. Ho, P. et al. (2010). Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum. Mutat. 31, 561-568. doi: 10. 1002/humu. 21225
56. Veeman, M. T. Slusarski, D. C. Kaykas, A. Louie, S. H. and Moon, R. T. (2003). Zebrafish prickle, a modulator of noncanonical Wnt/Fz signaling, regulates gastrulation movements. Curr. Biol. 13, 680-685. doi: 10. 1016/S0960-9822(03)00240-9
57. West, A. B. Moore, D. J. Choi, C. Andrabi, S. A. Li, X. Dikeman, D. et al. (2007). Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 16, 223-232. doi: 10. 1093/hmg/ddl471
58. Xiong, Y. Coombes, C. E. Kilaru, A. Li, X. Gitler, A. D. Bowers, W. J. et al. (2010). GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet. 6:e1000902. doi: 10. 1371/journal. pgen. 1000902
59. Zhu, P. P. Soderblom, C. Tao-Cheng, J. H. Stadler, J. and Blackstone, C. (2006). SPG3A protein atlastin-1 is enriched in growth cones and promotes axon elongation during neuronal development. Hum. Mol. Genet. 15, 1343-1353. doi: 10. 1093/hmg/ddl054
60. Zimprich, A. Biskup, S. Leitner, P. Lichtner, P. Farrer, M. Lincoln, S. et al. (2004). Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607. doi: 10. 1016/j. neuron. 2004. 11. 005